Alvotech (NASDAQ: ALVO) Rises 19% on New BofA Buy Rating

Nitish Kishor

25 August 2026 06:27 AM PDT

ALVO

Start Your Free Trial Now!

Image Source: Shutterstock

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Key Highlights

Alvotech shares closed up 19% at $5.27.
BofA Securities initiated coverage on the biosimilar specialist with a Buy rating.
BofA set a $7 price target.
The firm cited a positive outlook for the company's development pipeline and market position.

Alvotech (NASDAQ: ALVO) shares closed up 19% at $5.27 as BofA Securities initiated coverage on the biosimilar specialist with a Buy rating and a $7 price target.

What Happened

BofA cited a positive outlook for the company's development pipeline and market position in initiating coverage.

Market Reaction

Shares rose sharply as investors responded to the new Buy rating and price target, which implies meaningful upside from the stock's prior trading level.

Outlook

Continued execution on Alvotech's biosimilar pipeline and market positioning, now backed by BofA's coverage, is likely to remain relevant for the stock going forward.

FAQs

Q: Why did Alvotech shares rise 19%?

A: Shares rose after BofA Securities initiated coverage with a Buy rating and a $7 price target.

Q: What did BofA cite for its rating?

A: A positive outlook for the company's development pipeline and market position.

Q: What is Alvotech's business focus?

A: It is a biosimilar specialist.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

Kalkine Equities LLC, with Delaware File Number 4697384, Foreign Qualification Registration in California File Number 202109211078, and Texas File Number 805521396, is authorized to provide general advice only. The information on https://kalkine.com/ does not take into account any of your investment objectives, financial situation or needs. You should consider the appropriateness of advice taking into account your own objectives, financial situation and needs and seek independent financial advice before making any financial decisions. The link to our Terms and Conditions and Privacy Policy has been provided for your reference. On the date of publishing the reports (mentioned on the website), employees and/or associates of Kalkine do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations later.